TRANSCEND-CKD (NCT05936151) designates iohexol plasma clearance as its primary endpoint rather than creatinine-derived eGFR. In obesity-related CKD, creatinine equations carry systematic muscle-mass biases, and retatrutide's substantial weight reduction further shifts creatinine generation. Iohexol mGFR eliminates both noise sources, enabling the trial to detect a true pharmacological signal on kidney function.
Why Does Creatinine-Based eGFR Fail as a Primary Endpoint in Obesity-Related CKD Trials?
Creatinine-based eGFR equations derive GFR estimates from serum creatinine, whose generation is proportional to skeletal muscle mass. In obesity, elevated lean mass raises baseline creatinine production, causing CKD-EPI to underestimate true GFR by a clinically meaningful margin. Rothberg and colleagues (NDT 2024) identified this as the central methodological problem for kidney-outcome trials in obese populations receiving weight-loss pharmacotherapy.
The bias operates in two directions across the arc of a weight-loss trial. At baseline, elevated muscle mass in obese participants inflates serum creatinine relative to true GFR, causing eGFR to underestimate actual kidney function. Chang and colleagues (2018) showed that CKD-EPI and MDRD overestimate the prevalence of CKD stages 3–4 in severe obesity by misclassifying participants whose true GFR is normal.
As weight loss proceeds, skeletal muscle is lost alongside fat. Declining muscle mass reduces creatinine generation, lowering serum creatinine and producing an apparent eGFR rise that reflects reduced creatinine production rather than improved kidney filtration. This pharmacokinetic artifact is indistinguishable from true renoprotection when eGFR is the sole endpoint.
Cystatin C-based eGFR partially mitigates the muscle-mass confound because cystatin C generation is less dependent on skeletal muscle. However, cystatin C is influenced by thyroid status, corticosteroid use, and adiposity itself, all of which shift during major weight loss, making it an imperfect substitute for direct GFR measurement in this population.
How Does Iohexol Plasma Clearance Measure GFR, and Why Is It Methodologically Superior Here?
Iohexol is a non-ionic contrast agent that undergoes exclusive glomerular filtration with no tubular secretion, reabsorption, or extrarenal elimination. Its plasma clearance after a single intravenous bolus directly reflects GFR without dependence on endogenous biomarker generation. Delanaye and colleagues (2016) established iohexol clearance as the reference-standard mGFR method for clinical trials, citing low interlaboratory variability and analyte stability.
The measurement protocol involves a single intravenous injection of iohexol followed by timed blood sampling, typically at 2 and 5 hours post-injection. Plasma iohexol concentration is quantified by high-performance liquid chromatography or mass spectrometry. GFR is calculated from the area under the plasma concentration–time curve using the Brøchner-Mortensen equation for single-pool clearance.
Iohexol clearance is unaffected by changes in muscle mass, dietary protein intake, or the metabolic shifts accompanying major weight loss. Any change in mGFR in a retatrutide-treated participant therefore reflects a genuine change in glomerular filtration capacity rather than a creatinine-generation artifact.
TRANSCEND-CKD's design paper (Heerspink and colleagues, NDT 2026, doi:10.1093/ndt/gfaf230) specifies iohexol mGFR as the primary endpoint for precisely this reason. The practical limitation of iohexol mGFR is logistical, requiring an intravenous injection and timed blood draws that add procedural burden relative to a serum creatinine measurement.
How Does Retatrutide's Weight-Loss Magnitude Specifically Amplify the eGFR Artifact Problem?
Retatrutide produces weight reductions of approximately 17–24% at 48 weeks across phase 2 dose groups, generating proportionally large lean-mass losses and correspondingly large creatinine-generation decreases. At these weight-loss levels, the creatinine-derived eGFR artifact would be large enough to mimic a clinically meaningful renoprotective signal, making eGFR an unreliable primary endpoint for this compound at its studied doses.
The phase 2 obesity trial (Jastreboff and colleagues, NEJM 2023) reported mean weight reductions of 17.5% at 8 mg and 24.2% at 12 mg over 48 weeks. Lean body mass typically constitutes 20 to 30% of total weight lost during pharmacological obesity treatment, implying lean-mass reductions of 3 to 7% at these dose levels.
Nankivell and colleagues (2020) demonstrated that only 24 to 38% of eGFR results fall within 10% of simultaneously measured GFR. This precision gap widens further when creatinine generation is actively shifting during weight loss.
The phase 2 post-hoc kidney analysis (Heerspink and colleagues, Kidney International Reports 2025, PMC12231004) found that higher retatrutide doses were associated with increased eGFR in participants with obesity without T2D. The analysis acknowledged that this signal could not be separated from the creatinine-artifact effect of lean-mass loss. TRANSCEND-CKD's iohexol endpoint directly addresses this limitation.
This artifact problem is not unique to retatrutide. Any weight-loss pharmacotherapy producing substantial lean-mass reduction will generate a spurious eGFR rise. What makes retatrutide distinctive is the magnitude: its 24% weight-loss ceiling at 12 mg exceeds that of semaglutide 2.4 mg (approximately 15%) and tirzepatide (approximately 20%), making the artifact proportionally larger.
What Are the Specific Design Features of TRANSCEND-CKD That Operationalise the Iohexol mGFR Endpoint?
TRANSCEND-CKD enrolls approximately 146 adults with BMI ≥27 kg/m² and CKD stages 2–4, randomised 2:1 to retatrutide 8 mg or placebo. The primary endpoint is change in iohexol-measured GFR from baseline to Week 24. Secondary endpoints include UACR, kidney structural biomarkers, and creatinine-based eGFR, retained as a comparator to quantify the artifact gap between mGFR and eGFR.
The two-to-one randomisation ratio maximises pharmacodynamic data in the active arm while retaining a placebo reference for endpoint attribution. The 8 mg dose was selected based on the phase 2 kidney signal, which showed the strongest UACR reduction at 8 mg in the T2D+obesity subgroup, a reduction of 28.0% at 48 weeks.
SGLT2 inhibitors and GLP-1 receptor agonists are excluded from background therapy. Both drug classes independently alter creatinine handling and GFR, and their inclusion would introduce additional confounders into the mGFR signal. The exclusion also means TRANSCEND-CKD cannot address whether retatrutide's kidney effects are additive to these agents.
The Week 24 primary endpoint timepoint was selected to capture the acute-to-chronic GFR transition within the feasible window for a Phase 2b mechanistic study. At 24 weeks, the acute hemodynamic GFR shift from retatrutide's GLP-1R-mediated afferent arteriolar effects should have stabilised, allowing the mGFR measurement to reflect a more durable pharmacological state.
What Will the Comparison Between mGFR and eGFR Within TRANSCEND-CKD Reveal About Measurement Bias?
Because TRANSCEND-CKD collects both iohexol mGFR and creatinine-based eGFR at the same timepoints, it will generate the first prospective, within-participant quantification of the eGFR artifact in a retatrutide-treated CKD population. The magnitude of divergence between mGFR and eGFR trajectories will directly measure how much of the phase 2 eGFR signal was creatinine artifact versus true filtration change.
This within-trial comparison is a secondary endpoint of TRANSCEND-CKD, but its scientific value may exceed the primary efficacy result for the broader field. If the divergence between mGFR and eGFR trajectories is large, for example eGFR rising 5 mL/min/1.73m² while mGFR is unchanged, it would establish a quantitative correction factor applicable to interpreting eGFR data from other GLP-1RA trials in obese populations.
Conversely, if mGFR and eGFR trajectories converge, both rising or both stable, it would provide reassurance that creatinine-based endpoints are not systematically misleading in this context. This convergence or divergence finding will inform endpoint selection for any subsequent Phase 3 kidney-outcomes trial of retatrutide.
Does Retatrutide's Triple-Receptor Profile Produce Mechanistic Predictions Distinguishable by mGFR That eGFR Cannot Resolve?
Yes. Retatrutide's GLP-1R, GIPR, and GCGR components each exert distinct effects on renal hemodynamics and tubular function that would produce different mGFR trajectories if operative. GLP-1R agonism reduces intraglomerular pressure via afferent arteriolar effects. GCGR agonism is downregulated in CKD kidneys, creating a receptor-density-dependent effect that only mGFR can cleanly quantify against creatinine-generation noise.
GLP-1R activation in the proximal tubule reduces NHE3-mediated sodium reabsorption, lowering tubuloglomerular feedback tone and decreasing afferent arteriolar resistance. This hemodynamic sequence can transiently increase single-nephron GFR in hyperfiltrating kidneys before the downstream reduction in intraglomerular pressure produces a chronic GFR-stabilising effect. The net mGFR trajectory depends on which phase dominates at the Week 24 measurement window.
GCGR's renal role is complicated by the finding of Wang and colleagues (Cell Metabolism 2024) that renal GCGR expression is downregulated in CKD. If GCGR receptor density is reduced in TRANSCEND-CKD's CKD stages 2–4 population, the glucagon-receptor component of retatrutide's pharmacology may contribute less to the mGFR signal than in a non-CKD population. Only a direct mGFR measurement can isolate this receptor-density-dependent effect from creatinine-generation noise.
GIPR's renal expression is concentrated in the proximal tubule, where it modulates oxidative stress and NF-κB-driven inflammatory signalling. Its contribution to GFR is likely indirect, operating through tubular protection rather than direct hemodynamic GFR modulation. An mGFR endpoint captures the net GFR output of all three receptor pathways without the creatinine-generation noise that would obscure their individual contributions in an eGFR-based analysis.
What Are the Broader Implications of TRANSCEND-CKD's Endpoint Choice for GLP-1RA Kidney Trials in Obese Populations?
TRANSCEND-CKD's iohexol mGFR primary endpoint establishes a methodological precedent for kidney-outcome trials of high-efficacy weight-loss agents. If the trial demonstrates substantial mGFR–eGFR divergence in retatrutide-treated participants, it will challenge the validity of eGFR-based kidney endpoints in prior and ongoing GLP-1RA trials enrolling obese populations, including secondary kidney analyses from FLOW and SURMOUNT-related datasets.
The FLOW trial (Perkovic and colleagues, NEJM 2024) used eGFR-based composite endpoints in a T2D+CKD population with mean BMI approximately 33 kg/m². The 24% kidney-failure risk reduction was driven primarily by hard endpoints, dialysis initiation and sustained 50% eGFR decline, that are less susceptible to the creatinine artifact than continuous eGFR slope measures. However, secondary eGFR slope analyses in FLOW are potentially confounded by lean-mass changes accompanying semaglutide's approximately 5% weight reduction.
For future Phase 3 kidney-outcomes trials of retatrutide, requiring hard endpoints like kidney failure or sustained 40% eGFR decline, the TRANSCEND-CKD mGFR data will inform whether eGFR-based endpoints are defensible. The FDA's 2019 guidance on surrogate endpoints in CKD trials was written before the era of high-efficacy weight-loss pharmacotherapy and does not address the creatinine-artifact problem in this specific context.
For the broader mechanistic context of retatrutide's cardiometabolic evidence base, see What Do the 2026 TRIUMPH-1 Topline Data Show for Retatrutide's Weight Loss and Cardiometabolic Endpoints at 80 Weeks? For the GLP-1R class kidney mechanism review, see What Does the 2026 Comprehensive Review Reveal About Semaglutide's Cardioprotective and Nephroprotective Mechanisms in Cardiorenal Syndrome? For the GIPR agonism mechanistic debate, see Does Blocking the GIP Receptor Enhance Weight Loss, or Does GIPR Agonism Drive Obesity Treatment in 2026? Does Retatrutide Preserve More Lean Mass Than Semaglutide During Rapid Fat Loss in Adults With Obesity in 2026? Does Retatrutide's Phase 3 Evidence in 2026 Show Clinically Meaningful Weight Loss Beyond Semaglutide and Tirzepatide? Can Growth Hormone Peptides Counter the 30% Lean Mass Loss Risk During GLP-1 Monotherapy in 2026?